Cognitive Impairment Associated with Schizophrenia-CIAS - Pipeline Insight, 2024

This “Cognitive Impairment Associated with Schizophrenia-CIAS- Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cognitive Impairment Associated with Schizophrenia-CIAS pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cognitive Impairment Associated with Schizophrenia-CIAS Understanding

Cognitive Impairment Associated with Schizophrenia-CIAS: Overview

Schizophrenia is a serious mental disorder affecting approximately 1% of the US population and 24 million people worldwide. It is characterized by the occurrence of positive symptoms, such as hallucinations or delusions, and negative symptoms, such as affective flattening, and social withdrawal. Though schizophrenia affects a relatively small proportion of the population, it incurs substantial individual, societal, and healthcare costs. Cognitive deficits are not yet included in the diagnostic criteria for schizophrenia, but are considered a core feature of schizophrenia symptomatology. While neuropsychological impairment may not be present in all patients with schizophrenia, almost all patients with schizophrenia display some cognitive impairment in comparison with healthy controls. Cognitive impairments are often fully developed when patients present with a first episode of illness. Impairment occurs in most aspects of cognition, including attention, verbal learning and memory, secondary memory, working memory and executive functions. In most cases, cognitive impairments do not worsen or improve with illness progression. Treatments available for schizophrenia include typical and atypical antipsychotics, which predominantly target the positive symptoms of schizophrenia. Despite the availability of antipsychotic medications, patients with schizophrenia are often unsuccessful in re-entering the community and treatments do not appear to improve cognitive function beyond practice effects. Therefore, treatments for cognitive impairment have been identified as an unmet need. Cognitive deficits are one of the core symptoms of schizophrenia that evolve during the course of schizophrenia, after being originated even before the onset of illness.

Cognitive Impairment Associated with Schizophrenia-CIAS- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cognitive Impairment Associated with Schizophrenia-CIAS pipeline landscape is provided which includes the disease overview and Cognitive Impairment Associated with Schizophrenia-CIAS treatment guidelines. The assessment part of the report embraces, in depth Cognitive Impairment Associated with Schizophrenia-CIAS commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cognitive Impairment Associated with Schizophrenia-CIAS collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cognitive Impairment Associated with Schizophrenia-CIAS R&D. The therapies under development are focused on novel approaches to treat/improve Cognitive Impairment Associated with Schizophrenia-CIAS.

Cognitive Impairment Associated with Schizophrenia-CIAS Emerging Drugs Chapters

This segment of the Cognitive Impairment Associated with Schizophrenia-CIAS report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cognitive Impairment Associated with Schizophrenia-CIAS Emerging Drugs

RL-007: Recognify Life Sciences RL-007 is a neuromodulator that potently enhances synaptic plasticity by modulating excitatory neurotransmission and the cholinergic and gamma-aminobutyric acid type B (GABA type B) receptor systems, all of which are central to learning and memory functions. With its unique mechanism of action, atai believes RL-007 may enhance pro-cognitive functioning, such as neuronal signaling, learning, and memory. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Cognitive Impairment Associated withSchizophrenia.

BIIB104: Biogen BIIB104 is an AMPA receptor potentiator designed to facilitate neurotransmission in the central nervous system, a process which can be disrupted in a number of neurological diseases and neurocognitive disorders, including schizophrenia. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Cognitive Impairment Associated withSchizophrenia.

Luvadaxistat: Takeda Luvadaxistat is a potential first-in-class, investigational, oral, selective inhibitor with a high binding affinity to d-amino acid oxidase (DAAO). It targets glutamate, an abundant neurotransmitter in the brain. In schizophrenia, N-methyl D-aspartate (NMDA) receptor hypofunction on PV+ gamma-aminobutyric acid (GABA) interneurons results in disinhibition of cortical or hippocampal glutamate neurons projecting to the pyramidal neurons. The cortical disturbances account for the negative/cognitive symptoms of schizophrenia, while the downstream subcortical dopamine release manifests as the positive symptoms of thedisorder.

Cognitive Impairment Associated with Schizophrenia-CIAS: Therapeutic Assessment

This segment of the report provides insights about the different Cognitive Impairment Associated with Schizophrenia-CIAS drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cognitive Impairment Associated with Schizophrenia-CIAS

There are approx. 5+ key companies which are developing the therapies for Cognitive Impairment Associated with Schizophrenia-CIAS. The companies which have their Cognitive Impairment Associated with Schizophrenia-CIAS drug candidates in the most advanced stage, i.e. phase II include, Recognify Life Sciences.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

:
Route of Administration
Cognitive Impairment Associated with Schizophrenia-CIAS pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cognitive Impairment Associated with Schizophrenia-CIAS: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cognitive Impairment Associated with Schizophrenia-CIAS therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cognitive Impairment Associated with Schizophrenia-CIAS drugs.

Cognitive Impairment Associated with Schizophrenia-CIAS Report Insights

• Cognitive Impairment Associated with Schizophrenia-CIAS Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cognitive Impairment Associated with Schizophrenia-CIAS Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cognitive Impairment Associated with Schizophrenia-CIAS drugs?
• How many Cognitive Impairment Associated with Schizophrenia-CIAS drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cognitive Impairment Associated with Schizophrenia-CIAS?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cognitive Impairment Associated with Schizophrenia-CIAS therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cognitive Impairment Associated with Schizophrenia-CIAS and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Recognify Life Sciences
• Biogen
• Takeda
• Hoffmann-La Roche
• Astellas Pharma

Key Products

• RL-007
• BIIB104
• Luvadaxistat
• Basmisanil
• ASP4345

This product will be delivered within 1-3 business days.